Dr Reddy's Laboratories Wednesday announced the launch of Atomoxetine capsules used to treat attention-deficit hyperactivity disorder (ADHD) in the US market.
The Hyderabad-based company has received the approval from the US Food and Drug Administration (USFDA) to market its product which is a generic equivalent of Eli Lilly and Company's Straterra, Dr Reddy's Laboratories said in a statement.
As per the IMS Health sales data, the Strattera brand had US sales of around $304 million for the most recent 12 months ending in August 2018.
Shares of Dr Reddy's Laboratories were trading 1.87 per cent down at Rs 2,549 on the BSE.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.